Skip to main content
CRBP
NASDAQ Life Sciences

Corbus Activates $127.5M ATM, Adding Dilution Overhang to Cash-Burning Biotech

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.77
Mkt Cap
$188.428M
52W Low
$7.12
52W High
$20.56
52W Position info
37% above low
Off High info
52% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CRBP sits 37% above its 52-week low of $7.12.

Summary

Corbus Pharmaceuticals activated a $127.5 million at-the-market equity program, adding significant dilution potential just as the company burns cash ahead of critical clinical milestones.


Key Events · Financing and Capital Events · CRBP

  • $127.5M ATM Program Activated

    A prospectus supplement was filed to sell up to $127.5 million in common stock through Jefferies, with a 3% commission, under the existing $300 million shelf registration.

  • Potential 70% Share Count Increase

    At the assumed $9.40 offering price, the ATM could add 13.56 million shares, increasing outstanding shares to ~32.97 million — a roughly 70% increase — with immediate dilution of $2.46 per share to new investors.

  • Ongoing ATM Sales Already Underway

    Between June 30 and August 6, 2026, the company sold 738,707 shares under the Sale Agreement, raising approximately $6.6 million in proceeds.

  • Cash Runway Reliant on Dilution

    The ATM is critical to funding operations, as Corbus reported a wider Q2 loss of $35.0 million and stated its 12-month cash runway depends on continued ATM sales.


Analysis · CRBP · Life Sciences

Just one day after reporting a wider Q2 loss and a cash runway that depends on ongoing dilution, Corbus Pharmaceuticals filed a prospectus supplement to sell up to $127.5 million in common stock through an at-the-market (ATM) program with Jefferies. This move activates the $300 million shelf registration from March 2026 and quantifies the potential dilution: at an assumed price of $9.40, the offering would add 13.56 million shares, swelling the share count by roughly 70% and immediately diluting new investors by $2.46 per share. The company also revealed it had already sold 738,707 shares under this agreement between June 30 and August 6, raising about $6.6 million. For a clinical-stage biotech burning over $30 million per quarter, the ATM provides essential funding but creates a persistent overhang that could cap share price appreciation, especially with key data readouts for CRB-913 in September 2026 and the start of the TEMPO-1 trial on the horizon.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRBP was trading at $9.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $188.4M. The 52-week trading range was $7.12 to $20.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRBP - Latest Insights

CRBP
Nov 16, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $3.02 info
Change: -$0.4325 (-13%) info
Market Cap: $62.129M info
CRBP
Nov 10, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $3.02 info
Change: -$0.505 (-14%) info
Market Cap: $62.129M info
CRBP
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.08
Real-time Price: $3.02 info
Change: -$4.06 (-57%) info
Market Cap: $62.129M info
CRBP
Sep 14, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.26
Real-time Price: $3.02 info
Change: -$6.24 (-67%) info
Market Cap: $62.129M info
CRBP
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.91
Real-time Price: $3.02 info
Change: -$5.90 (-66%) info
Market Cap: $62.129M info